IRLAB-A IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders. It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About IRLAB Therapeutics (STO: IRLAB-A)
›
IRLAB Therapeutics (STO: IRLAB-A) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 31 employees.
The shares were at 0.7290 SEK on 20 November 2026, down 69.4% over 52 weeks. Its 52-week range is 0.5600 SEK to 2.455 SEK: the price is 70.3% below the high and 30.2% above the low.
Its market capitalisation is 108.41M SEK.
IRLAB Therapeutics reports return on equity of -358.1%, an operating margin of -47.9% and revenue down 47.7% year over year.
It holds more cash than debt, a net cash position of 72.71M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.